A proteomic portrait of atherosclerosis

Journal of Proteomics

Volumn 82, Issue , 2013, Pages 92-112

  Eberini, Ivano ^a,b   Wait, Robin ^c   Calabresi, Laura ^b,d   Sensi, Cristina ^a,b   Miller, Ingrid ^e   Gianazza, Elisabetta ^a,b  

^a Gruppo di Studio per la Proteomica e la Struttura delle Proteine   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d Centro Universitario per le Dislipidemie presso l'Ospedale di Niguarda   (Italy)

^e UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Acute myocardial infarction; Atheromatous plaque; Endothelial cells; Smooth muscle cells; Thrombus

Indexed keywords

LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ARTERY WALL; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMAN; INTIMA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEOMICS; REVIEW; SMOOTH MUSCLE FIBER; THROMBUS; TUNICA MEDIA; URINALYSIS;

ANIMALS; ATHEROSCLEROSIS; BLOOD PROTEINS; HUMANS; PROTEOME; PROTEOMICS;

EID: 84875671435     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.02.007     Document Type: Review

References (186)

1. Liu Y., Dalal K. Review of cost-effectiveness analysis of medical treatment for myocardial infarction. Int J Prev Med 2011, 2:64-72.
2. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
3. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011, 17:1410-1422.
4. Lovering R.C., Dimmer E.C., Talmud P.J. Improvements to cardiovascular gene ontology. Atherosclerosis 2009, 205:9-14.
5. Naghavi M., Libby P., Falk E., Casscells S.W., Litovsky S., Rumberger J., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003, 108:1772-1778.
6. Naghavi M., Libby P., Falk E., Casscells S.W., Litovsky S., Rumberger J., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664-1672.
7. Nordon I., Brar R., Hinchliffe R., Cockerill G., Loftus I., Thompson M. The role of proteomic research in vascular disease. J Vasc Surg 2009, 49:1602-1612.
8. Gianazza E., Eberini I., Villa P., Fratelli M., Pinna C., Wait R., et al. Monitoring the effects of drug treatment in rat models of disease by serum protein analysis. J. Chromatogr. B 2002, 771:107-130.
9. Guerini Rocco A., Mollica L., Gianazza E., Calabresi L., Franceschini G., Sirtori C.R., et al. A model structure for the heterodimer apoA-IMilano-apoA-II supports its peculiar susceptibility to proteolysis. Biophys J 2006, 91:3043-3049.
10. Eberini I., Gianazza E., Calabresi L., Sirtori C.R. ApoA-IMilano from structure to clinical application. Ann Med 2008, 40:48-56.
11. Rocco A.G., Gianazza E., Calabresi L., Sensi C., Franceschini G., Sirtori C.R., et al. Structural features and dynamics properties of human apolipoprotein A-I in a model of synthetic HDL. J Mol Graph Model 2009, 28:305-312.
12. Rocco A.G., Sensi C., Gianazza E., Calabresi L., Franceschini G., Sirtori C.R., et al. Structural and dynamic features of apolipoprotein A-I cysteine mutants, Milano and Paris, in synthetic HDL. J Mol Graph Model 2010, 29:406-414.
13. Fuster J.J., Castillo A.I., Zaragoza C., Ibanez B., Andres V. Animal models of atherosclerosis. Prog Mol Biol Transl Sci 2012, 105:1-23.
14. Zaragoza C., Gomez-Guerrero C., Martin-Ventura J.L., Blanco-Colio L., Lavin B., Mallavia B., et al. Animal models of cardiovascular diseases. J Biomed Biotechnol 2011, 2011:497841.
15. Daugherty A., Lu H., Howatt D.A., Rateri D.L. Modes of defining atherosclerosis in mouse models: relative merits and evolving standards. Methods Mol Biol 2009, 573:1-15.
16. Meir K.S., Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 2004, 24:1006-1014.
17. Zadelaar S., Kleemann R., Verschuren L., de Vries-Van der Weij J., van der Hoorn J., Princen H.M., et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007, 27:1706-1721.
18. Kolovou G., Anagnostopoulou K., Mikhailidis D.P., Cokkinos D.V. Apolipoprotein E knockout models. Curr Pharm Des 2008, 14:338-351.
19. Vilahur G., Padro T., Badimon L. Atherosclerosis and thrombosis: insights from large animal models. J Biomed Biotechnol 2011, 2011:907575.
20. de la Cuesta F., Alvarez-Llamas G., Maroto A.S., Donado A., Juarez-Tosina R., Rodriguez-Padial L., et al. An optimum method designed for 2-D DIGE analysis of human arterial intima and media layers isolated by laser microdissection. Proteomics Clin Appl 2009, 3:1174-1184.
21. de la Cuesta F., Alvarez-Llamas G., Maroto A.S., Donado A., Zubiri I., Posada M., et al. A proteomic focus on the alterations occurring at the human atherosclerotic coronary intima. Mol Cell Proteomics 2011, 10. [M110 003517].
22. Ades E.W., Candal F.J., Swerlick R.A., George V.G., Summers S., Bosse D.C., et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992, 99:683-690.
23. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973, 52:2745-2756.
24. Baudin B., Bruneel A., Bosselut N., Vaubourdolle M. A protocol for isolation and culture of human umbilical vein endothelial cells. Nat Protoc 2007, 2:481-485.
25. Nguyen V.P., Hanna G., Rodrigues N., Pizzuto K., Yang E., Van Slyke P., et al. Differential proteomic analysis of lymphatic, venous, and arterial endothelial cells extracted from bovine mesenteric vessels. Proteomics 2010, 10:1658-1672.
26. Lu L., Yang P.Y., Rui Y.C., Kang H., Zhang J., Zhang J.P., et al. Comparative proteome analysis of rat brain and coronary microvascular endothelial cells. Physiol Res 2007, 56:159-168.
27. Himburg H.A., Dowd S.E., Friedman M.H. Frequency-dependent response of the vascular endothelium to pulsatile shear stress. Am J Physiol Heart Circ Physiol 2007, 293:H645-H653.
28. Pellieux C., Desgeorges A., Pigeon C.H., Chambaz C., Yin H., Hayoz D., et al. Cap G, a gelsolin family protein modulating protective effects of unidirectional shear stress. J Biol Chem 2003, 278:29136-29144.
29. Qi Y.X., Jiang J., Jiang X.H., Wang X.D., Ji S.Y., Han Y., et al. PDGF-BB and TGF-{beta}1 on cross-talk between endothelial and smooth muscle cells in vascular remodeling induced by low shear stress. Proc Natl Acad Sci U S A 2011, 108:1908-1913.
30. Huang B., Chen S.C., Wang D.L. Shear flow increases S-nitrosylation of proteins in endothelial cells. Cardiovasc Res 2009, 83:536-546.
31. Zhao S., Suciu A., Ziegler T., Moore J.E., Burki E., Meister J.J., et al. Synergistic effects of fluid shear stress and cyclic circumferential stretch on vascular endothelial cell morphology and cytoskeleton. Arterioscler Thromb Vasc Biol 1995, 15:1781-1786.
32. Bruneel A., Labas V., Mailloux A., Sharma S., Vinh J., Vaubourdolle M., et al. Proteomic study of human umbilical vein endothelial cells in culture. Proteomics 2003, 3:714-723.
33. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115-126.
34. Athyros V.G., Kakafika A.I., Karagiannis A., Mikhailidis D.P. Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis 2008, 200:1-12.
35. Gonzalez-Cabrero J., Pozo M., Duran M.C., de Nicolas R., Egido J., Vivanco F. The proteome of endothelial cells. Methods Mol Biol 2007, 357:181-198.
36. Modrego J., Monux G., Mateos-Caceres P.J., Martinez-Lopez I., Segura A., Zamorano-Leon J.J., et al. Effects of platelets on the protein expression in aortic segments: a proteomic approach. J Cell Biochem 2010, 111:889-898.
37. Banfi C., Brioschi M., Wait R., Begum S., Gianazza E., Pirillo A., et al. Proteome of endothelial cell-derived procoagulant microparticles. Proteomics 2005, 5:4443-4455.
38. Epstein S.E. The multiple mechanisms by which infection may contribute to atherosclerosis development and course. Circ Res 2002, 90:2-4.
39. Tseng H.W., Juan H.F., Huang H.C., Lin J.Y., Sinchaikul S., Lai T.C., et al. Lipopolysaccharide-stimulated responses in rat aortic endothelial cells by a systems biology approach. Proteomics 2006, 6:5915-5928.
40. O'Toole T.E., Conklin D.J., Bhatnagar A. Environmental risk factors for heart disease. Rev Environ Health 2008, 23:167-202.
41. Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis 2009, 205:23-32.
42. Raveendran M., Senthil D., Utama B., Shen Y., Wang J., Zhang Y., et al. Effect of water-soluble fraction of cigarette smoke on human aortic endothelial cells - a proteomic approach. Cell Biol Toxicol 2005, 21:27-40.
43. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
44. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004, 84:1381-1478.
45. Kinumi T., Ogawa Y., Kimata J., Saito Y., Yoshida Y., Niki E. Proteomic characterization of oxidative dysfunction in human umbilical vein endothelial cells (HUVEC) induced by exposure to oxidized LDL. Free Radic Res 2005, 39:1335-1344.
46. Chen C.Y., Lee C.M., Hsu H.C., Yang C.Y., Chow L.P., Lee Y.T. Proteomic approach to study the effects of various oxidatively modified low-density lipoprotein on regulation of protein expression in human umbilical vein endothelial cell. Life Sci 2007, 80:2469-2480.
47. Zimman A., Chen S.S., Komisopoulou E., Titz B., Martinez-Pinna R., Kafi A., et al. Activation of aortic endothelial cells by oxidized phospholipids: a phosphoproteomic analysis. J Proteome Res 2010, 9:2812-2824.
48. Tunica D.G., Yin X., Sidibe A., Stegemann C., Nissum M., Zeng L., et al. Proteomic analysis of the secretome of human umbilical vein endothelial cells using a combination of free-flow electrophoresis and nanoflow LC-MS/MS. Proteomics 2009, 9:4991-4996.
49. Sprenger R.R., Fontijn R.D., van Marle J., Pannekoek H., Horrevoets A.J. Spatial segregation of transport and signalling functions between human endothelial caveolae and lipid raft proteomes. Biochem J 2006, 400:401-410.
50. Wang T., Chen Z., Wang X., Shyy J.Y., Zhu Y. Cholesterol loading increases the translocation of ATP synthase beta chain into membrane caveolae in vascular endothelial cells. Biochim Biophys Acta 2006, 1761:1182-1190.
51. Wu J., Liu W., Sousa E., Qiu Y., Pittman D.D., Maganti V., et al. Proteomic identification of endothelial proteins isolated in situ from atherosclerotic aorta via systemic perfusion. J Proteome Res 2007, 6:4728-4736.
52. Siow R.C., Pearson J.D. Vascular smooth muscle cells: isolation, culture, and characterization. Methods Mol Med 2001, 46:237-245.
53. Golovina V.A., Blaustein M.P. Preparation of primary cultured mesenteric artery smooth muscle cells for fluorescent imaging and physiological studies. Nat Protoc 2006, 1:2681-2687.
54. Chamley-Campbell J., Campbell G.R., Ross R. The smooth muscle cell in culture. Physiol Rev 1979, 59:1-61.
55. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84:767-801.
56. Cecchettini A., Rocchiccioli S., Boccardi C., Citti L. Vascular smooth-muscle-cell activation: proteomics point of view. Int Rev Cell Mol Biol 2011, 288:43-99.
57. Li S., Sims S., Jiao Y., Chow L.H., Pickering J.G. Evidence from a novel human cell clone that adult vascular smooth muscle cells can convert reversibly between noncontractile and contractile phenotypes. Circ Res 1999, 85:338-348.
58. Boettger T., Beetz N., Kostin S., Schneider J., Kruger M., Hein L., et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009, 119:2634-2647.
59. Potta S.P., Liang H., Pfannkuche K., Winkler J., Chen S., Doss M.X., et al. Functional characterization and transcriptome analysis of embryonic stem cell-derived contractile smooth muscle cells. Hypertension 2009, 53:196-204.
60. Mayr U., Mayr M., Yin X., Begum S., Tarelli E., Wait R., et al. Proteomic dataset of mouse aortic smooth muscle cells. Proteomics 2005, 5:4546-4557.
61. Sukhanov S., Delafontaine P. Protein chip-based microarray profiling of oxidized low density lipoprotein-treated cells. Proteomics 2005, 5:1274-1280.
62. Camejo G., Hurt-Camejo E., Wiklund O., Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998, 139:205-222.
63. Padro T., Pena E., Garcia-Arguinzonis M., Llorente-Cortes V., Badimon L. Low-density lipoproteins impair migration of human coronary vascular smooth muscle cells and induce changes in the proteomic profile of myosin light chain. Cardiovasc Res 2008, 77:211-220.
64. Trott D., McManus C.A., Martin J.L., Brennan B., Dunn M.J., Rose M.L. Effect of phosphorylated hsp27 on proliferation of human endothelial and smooth muscle cells. Proteomics 2009, 9:3383-3394.
65. Garcia-Arguinzonis M., Padro T., Lugano R., Llorente-Cortes V., Badimon L. Low-density lipoproteins induce heat shock protein 27 dephosphorylation, oligomerization, and subcellular relocalization in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2010, 30:1212-1219.
66. Won K.J., Lee P., Jung S.H., Jiang X., Lee C.K., Lin H.Y., et al. 3-morpholinosydnonimine participates in the attenuation of neointima formation via inhibition of annexin A2-mediated vascular smooth muscle cell migration. Proteomics 2011, 11:193-201.
67. Mayr M., Zampetaki A., Sidibe A., Mayr U., Yin X., De Souza A.I., et al. Proteomic and metabolomic analysis of smooth muscle cells derived from the arterial media and adventitial progenitors of apolipoprotein E-deficient mice. Circ Res 2008, 102:1046-1056.
68. Wang Y., Zhang B., Bai Y., Zeng C., Wang X. Changes in proteomic features induced by insulin on vascular smooth muscle cells from spontaneous hypertensive rats in vitro. Cell Biochem Biophys 2010, 58:97-106.
69. Farina A., Chambery A., Esposito S., Agozzino L., Cotrufo M., Della Corte A., et al. Proteomic profiling of medial degeneration in human ascending aorta. Clin Biochem 2010, 43:387-396.
70. Fach E.M., Garulacan L.A., Gao J., Xiao Q., Storm S.M., Dubaquie Y.P., et al. In vitro biomarker discovery for atherosclerosis by proteomics. Mol Cell Proteomics 2004, 3:1200-1210.
71. Kang J.H., Ryu H.S., Kim H.T., Lee S.J., Choi U.K., Park Y.B., et al. Proteomic analysis of human macrophages exposed to hypochlorite-oxidized low-density lipoprotein. Biochim Biophys Acta 2009, 1794:446-458.
72. Yang P.Y., Rui Y.C., Yang P.Y., Yu Y.L. Proteomic analysis of foam cells. Methods Mol Biol 2007, 357:297-305.
73. Bagnato C., Thumar J., Mayya V., Hwang S.I., Zebroski H., Claffey K.P., et al. Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry. Mol Cell Proteomics 2007, 6:1088-1102.
74. Terzuoli L., Felici C., Ciari I., Guerranti R., Pagani R., Marinello E., et al. Synthetic gel of carotid artery plaque. Int J Immunopathol Pharmacol 2007, 20:637-642.
75. Porcelli B., Ciari I., Felici C., Pagani R., Banfi C., Brioschi M., et al. Proteomic analysis of atherosclerotic plaque. Biomed Pharmacother 2010, 64:369-372.
76. Stauffer B.L., Kushner E.J., Wulfman T., Zeller T., Sobus R., Westby C.M. Transcriptional regulation of beta2-microglobulin demonstrated via a novel genomic and proteomic analysis of percutaneously collected peripheral atheroma. Clin Transl Sci 2008, 1:240-244.
77. Lepedda A.J., Cigliano A., Cherchi G.M., Spirito R., Maggioni M., Carta F., et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis 2009, 203:112-118.
78. Olson F.J., Sihlbom C., Davidsson P., Hulthe J., Fagerberg B., Bergstrom G. Consistent differences in protein distribution along the longitudinal axis in symptomatic carotid atherosclerotic plaques. Biochem Biophys Res Commun 2010, 401:574-580.
79. de Kleijn D.P., Moll F.L., Hellings W.E., Ozsarlak-Sozer G., de Bruin P., Doevendans P.A., et al. Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol 2010, 30:612-619.
80. Pula G., Perera S., Prokopi M., Sidibe A., Boulanger C.M., Mayr M. Proteomic analysis of secretory proteins and vesicles in vascular research. Proteomics Clin Appl 2008, 2:882-891.
81. Duran M.C., Mas S., Martin-Ventura J.L., Meilhac O., Michel J.B., Gallego-Delgado J., et al. Proteomic analysis of human vessels: application to atherosclerotic plaques. Proteomics 2003, 3:973-978.
82. Martin-Ventura J.L., Duran M.C., Blanco-Colio L.M., Meilhac O., Leclercq A., Michel J.B., et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation 2004, 110:2216-2219.
83. Duran M.C., Boeri-Erba E., Mohammed S., Martin-Ventura J.L., Egido J., Vivanco F., et al. Characterization of HSP27 phosphorylation sites in human atherosclerotic plaque secretome. Methods Mol Biol 2007, 357:151-163.
84. de la Cuesta F., Barderas M.G., Calvo E., Zubiri I., Maroto A.S., Darde V.M., et al. Secretome analysis of atherosclerotic and non-atherosclerotic arteries reveals dynamic extracellular remodeling during pathogenesis. J Proteomics 2012, 75:2960-2971.
85. Brioschi M., Lento S., Tremoli E., Banfi C. Proteomic analysis of endothelial cell secretome: a means of studying the pleiotropic effects of Hmg-CoA reductase inhibitors. J Proteomics 2012, 78:346-361.
86. Duran M.C., Martin-Ventura J.L., Mohammed S., Barderas M.G., Blanco-Colio L.M., Mas S., et al. Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. Eur J Pharmacol 2007, 562:119-129.
87. Mayr M., Grainger D., Mayr U., Leroyer A.S., Leseche G., Sidibe A., et al. Proteomics, metabolomics, and immunomics on microparticles derived from human atherosclerotic plaques. Circ Cardiovasc Genet 2009, 2:379-388.
88. Hsu H.H., Artigues A., Villar M.T. Induction of calcification by serum depletion in cell culture: a model for focal calcification in aortas related to atherosclerosis. Lipids Health Dis 2008, 7:2.
89. Martel J., Young D., Young A., Wu C.Y., Chen C.D., Yu J.S., et al. Comprehensive proteomic analysis of mineral nanoparticles derived from human body fluids and analyzed by liquid chromatography-tandem mass spectrometry. Anal Biochem 2011, 418:111-125.
90. Heinecke J.W. The HDL, proteome: a marker - and perhaps mediator - of coronary artery disease. J Lipid Res 2009, 50:S167-S171. [Suppl.].
91. Davidsson P., Hulthe J., Fagerberg B., Camejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol 2010, 30:156-163.
92. Heinecke J.W. The protein cargo of HDL: implications for vascular wall biology and therapeutics. J Clin Lipidol 2010, 4:371-375.
93. Asztalos B.F., Tani M., Schaefer E.J. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011, 22:176-185.
94. Karlsson H., Leanderson P., Tagesson C., Lindahl M. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5:551-565.
95. Karlsson H., Leanderson P., Tagesson C., Lindahl M. Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5:1431-1445.
96. Collins L.A., Olivier M. Quantitative comparison of lipoprotein fractions derived from human plasma and serum by liquid chromatography-tandem mass spectrometry. Proteome Sci 2010, 8:42.
97. Davidsson P., Hulthe J., Fagerberg B., Olsson B.M., Hallberg C., Dahllof B., et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res 2005, 46:1999-2006.
98. King V.L., Thompson J., Tannock L.R. Serum amyloid A in atherosclerosis. Curr Opin Lipidol 2011, 22:302-307.
99. Navab M., Reddy S.T., Van Lenten B.J., Fogelman A.M. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011, 8:222-232.
100. Chiba T., Chang M.Y., Wang S., Wight T.N., McMillen T.S., Oram J.F., et al. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler Thromb Vasc Biol 2011, 31:1326-1332.
101. Ortiz-Munoz G., Houard X., Martin-Ventura J.L., Ishida B.Y., Loyau S., Rossignol P., et al. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J 2009, 23:3129-3139.
102. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007, 117:746-756.
103. Vaisar T., Mayer P., Nilsson E., Zhao X.Q., Knopp R., Prazen B.J. HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta 2010, 411:972-979.
104. Green P.S., Vaisar T., Pennathur S., Kulstad J.J., Moore A.B., Marcovina S., et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 2008, 118:1259-1267.
105. Banfi C., Brioschi M., Barcella S., Wait R., Begum S., Galli S., et al. Proteomic analysis of human low-density lipoprotein reveals the presence of prenylcysteine lyase, a hydrogen peroxide-generating enzyme. Proteomics 2009, 9:1344-1352.
106. Manocha M., Malinowski P., Li K., Macri J. Development of a 2-D apoB peptide profile to detect conformational changes associated with apoB-containing lipoproteins. Electrophoresis 2009, 30:2227-2233.
107. Eberini I., Calabresi L., Wait R., Tedeschi G., Pirillo A., Puglisi L., et al. Macrophage metalloproteinases degrade HDL-associated apoA-I at both the N- and the C-terminus. Biochem J 2002, 362:627-634.
108. Eberini I., Gianazza E., Breghi L., Klugmann S., Calabresi L., Gomaraschi M., et al. Apolipoprotein A-I breakdown is induced by thrombolysis in coronary patients. Ann Med 2007, 39:306-311.
109. M apoprotein: identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985, 37:1083-1097.
110. M apoprotein: decreased high density lipoprotein levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980, 66:892-900.
111. Gianazza E., Eberini I., Sirtori C.R., Franceschini G., Calabresi L. Size is a major determinant of dissociation and denaturation behaviour of reconstituted high-density lipoproteins. Biochem J 2002, 366:245-253.
112. Kim S.Y., Park S.M., Lee S.T. Apolipoprotein C-II is a novel substrate for matrix metalloproteinases. Biochem Biophys Res Commun 2006, 339:47-54.
113. Park J.H., Park S.M., Park S.H., Cho K.H., Lee S.T. Cleavage and functional loss of human apolipoprotein E by digestion of matrix metalloproteinase-14. Proteomics 2008, 8:2926-2935.
114. Park J.Y., Park J.H., Jang W., Hwang I.K., Kim I.J., Kim H.J., et al. Apolipoprotein A-IV is a novel substrate for matrix metalloproteinases. J Biochem 2011, 151:291-298.
115. Lee M., Kovanen P.T., Tedeschi G., Oungre E., Franceschini G., Calabresi L. Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux. J Lipid Res 2003, 44:539-546.
116. Bengtsson T., Karlsson H., Gunnarsson P., Skoglund C., Elison C., Leanderson P., et al. The periodontal pathogen Porphyromonas gingivalis cleaves apoB-100 and increases the expression of apoM in LDL in whole blood leading to cell proliferation. J Intern Med 2008, 263:558-571.
117. Bergt C., Pennathur S., Fu X., Byun J., O'Brien K., McDonald T.O., et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004, 101:13032-13037.
118. Shao B., Pennathur S., Heinecke J.W. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem 2012, 287:6375-6386.
119. Obama T., Kato R., Masuda Y., Takahashi K., Aiuchi T., Itabe H. Analysis of modified apolipoprotein B-100 structures formed in oxidized low-density lipoprotein using LC-MS/MS. Proteomics 2007, 7:2132-2141.
120. Ge J., Yan H., Li S., Nie W., Dong K., Zhang L., et al. Changes in proteomics profile during maturation of marrow-derived dendritic cells treated with oxidized low-density lipoprotein. Proteomics 2011, 11:1893-1902.
121. Nobecourt E., Davies M.J., Brown B.E., Curtiss L.K., Bonnet D.J., Charlton F., et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 2007, 50:643-653.
122. Nobecourt E., Tabet F., Lambert G., Puranik R., Bao S., Yan L., et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2010, 30:766-772.
123. Lapolla A., Brioschi M., Banfi C., Tremoli E., Cosma C., Bonfante L., et al. Nonenzymatically glycated lipoprotein ApoA-I in plasma of diabetic and nephropathic patients. Ann N Y Acad Sci 2008, 1126:295-299.
124. Shuvaev V.V., Fujii J., Kawasaki Y., Itoh H., Hamaoka R., Barbier A., et al. Glycation of apolipoprotein E impairs its binding to heparin: identification of the major glycation site. Biochim Biophys Acta 1999, 1454:296-308.
125. Barderas M.G., Darde V.M., Duran M.C., Egido J., Vivanco F. Characterization of circulating human monocytes by proteomic analysis. Methods Mol Biol 2007, 357:319-328.
126. Poduri A., Bahl A., Talwar K.K., Khullar M. Proteomic analysis of circulating human monocytes in coronary artery disease. Mol Cell Biochem 2012, 360:181-188.
127. Barderas M.G., Tunon J., Darde V.M., De la Cuesta F., Duran M.C., Jimenez-Nacher J.J., et al. Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. J Proteome Res 2007, 6:876-886.
128. Shamsara J., Behravan J., Falsoleiman H., Mohammadpour A.H., Rendeirs J., Ramezani M. Pentoxifylline administration changes protein expression profile of coronary artery disease patients. Gene 2011, 487:107-111.
129. Yu Y., Leng T., Yun D., Liu N., Yao J., Dai Y., et al. Global analysis of the rat and human platelet proteome - the molecular blueprint for illustrating multi-functional platelets and cross-species function evolution. Proteomics 2010, 10:2444-2457.
130. Eidelman O., Jozwik C., Huang W., Srivastava M., Rothwell S.W., Jacobowitz D.M., et al. Gender dependence for a subset of the low-abundance signaling proteome in human platelets. Hum. Genomics proteomics: HGP 2010, 2010:164906.
131. Winkler W., Zellner M., Diestinger M., Babeluk R., Marchetti M., Goll A., et al. Biological variation of the platelet proteome in the elderly population and its implication for biomarker research. Mol Cell Proteomics 2008, 7:193-203.
132. Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., Schutz C., et al. Phosphoproteome of resting human platelets. J Proteome Res 2008, 7:526-534.
133. Dowal L., Yang W., Freeman M.R., Steen H., Flaumenhaft R. Proteomic analysis of palmitoylated platelet proteins. Blood 2011, 118:e62-e73.
134. Maynard D.M., Heijnen H.F., Horne M.K., White J.G., Gahl W.A. Proteomic analysis of platelet alpha-granules using mass spectrometry. J Thromb Haemost 2007, 5:1945-1955.
135. Hernandez-Ruiz L., Valverde F., Jimenez-Nunez M.D., Ocana E., Saez-Benito A., Rodriguez-Martorell J., et al. Organellar proteomics of human platelet dense granules reveals that 14-3-3zeta is a granule protein related to atherosclerosis. J Proteome Res 2007, 6:4449-4457.
136. Coppinger J.A., Cagney G., Toomey S., Kislinger T., Belton O., McRedmond J.P., et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004, 103:2096-2104.
137. Piersma S.R., Broxterman H.J., Kapci M., de Haas R.R., Hoekman K., Verheul H.M., et al. Proteomics of the TRAP-induced platelet releasate. J Proteomics 2009, 72:91-109.
138. Lewandrowski U., Wortelkamp S., Lohrig K., Zahedi R.P., Wolters D.A., Walter U., et al. Platelet membrane proteomics: a novel repository for functional research. Blood 2009, 114:e10-e19.
139. Premsler T., Lewandrowski U., Sickmann A., Zahedi R.P. Phosphoproteome analysis of the platelet plasma membrane. Methods Mol Biol 2011, 728:279-290.
140. Kaiser W.J., Holbrook L.M., Tucker K.L., Stanley R.G., Gibbins J.M. A functional proteomic method for the enrichment of peripheral membrane proteins reveals the collagen binding protein Hsp47 is exposed on the surface of activated human platelets. J Proteome Res 2009, 8:2903-2914.
141. Finamore F., Pieroni L., Ronci M., Marzano V., Mortera S.L., Romano M., et al. Proteomics investigation of human platelets by shotgun nUPLC-MSE and 2DE experimental strategies: a comparative study. Blood Transfus 2010, 8(Suppl. 3):s140-s148.
142. Majek P., Reicheltova Z., Stikarova J., Suttnar J., Sobotkova A., Dyr J.E. Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Sci 2010, 8:56.
143. Tucker K.L., Kaiser W.J., Bergeron A.L., Hu H., Dong J.F., Tan T.H., et al. Proteomic analysis of resting and thrombin-stimulated platelets reveals the translocation and functional relevance of HIP-55 in platelets. Proteomics 2009, 9:4340-4354.
144. Thiele T., Steil L., Gebhard S., Scharf C., Hammer E., Brigulla M., et al. Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion 2007, 47:1221-1233.
145. Thon J.N., Schubert P., Duguay M., Serrano K., Lin S., Kast J., et al. Comprehensive proteomic analysis of protein changes during platelet storage requires complementary proteomic approaches. Transfusion 2008, 48:425-435.
146. Springer D.L., Miller J.H., Spinelli S.L., Pasa-Tolic L., Purvine S.O., Daly D.S., et al. Platelet proteome changes associated with diabetes and during platelet storage for transfusion. J Proteome Res 2009, 8:2261-2272.
147. Della Corte A., Tamburrelli C., Crescente M., Giordano L., D'Imperio M., Di Michele M., et al. Platelet proteome in healthy volunteers who smoke. Platelets 2011, 23:91-105.
148. Banfi C., Brioschi M., Marenzi G., De Metrio M., Camera M., Mussoni L., et al. Proteome of platelets in patients with coronary artery disease. Exp Hematol 2010, 38:341-350.
149. Parguina A.F., Grigorian-Shamajian L., Agra R.M., Teijeira-Fernandez E., Rosa I., Alonso J., et al. Proteins involved in platelet signaling are differentially regulated in acute coronary syndrome: a proteomic study. PLoS One 2010, 5:e13404.
150. Lopez-Farre A.J., Zamorano-Leon J.J., Azcona L., Modrego J., Mateos-Caceres P.J., Gonzalez-Armengol J., et al. Proteomic changes related to "bewildered" circulating platelets in the acute coronary syndrome. Proteomics 2011, 11:3335-3348.
151. Furie B., Furie B.C. Mechanisms of thrombus formation. N Engl J Med 2008, 359:938-949.
152. Ganesh S.K., Sharma Y., Dayhoff J., Fales H.M., Van Eyk J., Kickler T.S., et al. Detection of venous thromboembolism by proteomic serum biomarkers. PLoS One 2007, 2:e544.
153. Hong M., Zhang X., Hu Y., Wang H., He W., Mei H., et al. The potential biomarkers for thromboembolism detected by SELDI-TOF-MS. Thromb Res 2009, 123:556-564.
154. Ramacciotti E., Hawley A.E., Wrobleski S.K., Myers D.D., Strahler J.R., Andrews P.C., et al. Proteomics of microparticles after deep venous thrombosis. Thromb Res 2010, 125:e269-e274.
155. Martinelli I., Bucciarelli P., Mannucci P.M. Thrombotic risk factors: basic pathophysiology. Crit Care Med 2010, 38:S3-S9.
156. Arias-Salgado E.G., Larrucea S., Butta N., Fernandez D., Garcia-Munoz S., Parrilla R., et al. Variations in platelet protein associated with arterial thrombosis. Thromb Res 2008, 122:640-647.
157. Arbustini E., Dal Bello B., Morbini P., Gavazzi A., Specchia G., Vigano M. Immunohistochemical characterization of coronary thrombi in allograft vascular disease. Transplantation 2000, 69:1095-1101.
158. Francis C.W., Markham R.E., Marder V.J. Demonstration of in situ fibrin degradation in pathologic thrombi. Blood 1984, 63:1216-1224.
159. Gron B., Filion-Myklebust C., Bjornsen S., Haidaris P., Brosstad F. Cross-linked alpha s gamma t-chain hybrids in plasma clots studied by 1D- and 2D electrophoresis and western blotting. Thromb Haemost 1993, 70:438-442.
160. Annex B.H., Sketch M.H., Stack R.S., Phillips H.R. Transluminal extraction coronary atherectomy. Cardiol Clin 1994, 12:611-622.
161. Yao H., Shi P., Zhang L., Fan X., Shao Q., Cheng Y. Untargeted metabolic profiling reveals potential biomarkers in myocardial infarction and its application. Mol Biosyst 2010, 6:1061-1070.
162. Donahue M.P., Rose K., Hochstrasser D., Vonderscher J., Grass P., Chibout S.D., et al. Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma. Am Heart J 2006, 152:478-485.
163. Wilson A.M., Kimura E., Harada R.K., Nair N., Narasimhan B., Meng X.Y., et al. Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 2007, 116:1396-1403.
164. Fung E.T., Wilson A.M., Zhang F., Harris N., Edwards K.A., Olin J.W., et al. A biomarker panel for peripheral arterial disease. Vasc Med 2008, 13:217-224.
165. Wu A.H. Early detection of acute coronary syndromes and risk stratification by multimarker analysis. Biomark Med 2007, 1:45-57.
166. Gasparri C., Curcio A., Torella D., Gaspari M., Celi V., Salituri F., et al. Proteomics reveals high levels of vitamin D binding protein in myocardial infarction. Front Biosci (Elite Ed) 2010, 2:796-804.
167. Cubedo J., Padro T., Garcia-Moll X., Pinto X., Cinca J., Badimon L. Proteomic signature of apolipoprotein J in the early phase of new-onset myocardial infarction. J Proteome Res 2011, 10:211-220.
168. Cubedo J., Padro T., Alonso R., Cinca J., Mata P., Badimon L. Differential proteomic distribution of TTR (pre-albumin) forms in serum and HDL of patients with high cardiovascular risk. Atherosclerosis 2012, 222:263-269.
169. Haas B., Serchi T., Wagner D.R., Gilson G., Planchon S., Renaut J., et al. Proteomic analysis of plasma samples from patients with acute myocardial infarction identifies haptoglobin as a potential prognostic biomarker. J Proteomics 2011, 75:229-236.
170. Mateos-Caceres P.J., Garcia-Mendez A., Lopez Farre A., Macaya C., Nunez A., Gomez J., et al. Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol 2004, 44:1578-1583.
171. Florian-Kujawski M., Hussain W., Chyna B., Kahn S., Hoppensteadt D., Leya F., et al. Biomarker profiling of plasma from acute coronary syndrome patients. Application of ProteinChip Array analysis. Int Angiol 2004, 23:246-254.
172. Peronnet E., Becquart L., Poirier F., Cubizolles M., Choquet-Kastylevsky G., Jolivet-Reynaud C. SELDI-TOF MS analysis of the cardiac troponin I forms present in plasma from patients with myocardial infarction. Proteomics 2006, 6:6288-6299.
173. Darde V.M., de la Cuesta F., Dones F.G., Alvarez-Llamas G., Barderas M.G., Vivanco F. Analysis of the plasma proteome associated with acute coronary syndrome: does a permanent protein signature exist in the plasma of ACS patients?. J Proteome Res 2010, 9:4420-4432.
174. Wykrzykowska J.J., Garcia-Garcia H.M., Goedhart D., Zalewski A., Serruys P.W. Differential protein biomarker expression and their time-course in patients with a spectrum of stable and unstable coronary syndromes in the Integrated Biomarker and Imaging Study-1 (IBIS-1). Int J Cardiol 2011, 149:10-16.
175. Silbiger V.N., Luchessi A.D., Hirata R.D., Neto L.G., Pastorelli C.P., Ueda E.K., et al. Time course proteomic profiling of human myocardial infarction plasma samples: an approach to new biomarker discovery. Clin Chim Acta 2011, 412:1086-1093.
176. Patten R.D., Aronovitz M.J., Deras-Mejia L., Pandian N.G., Hanak G.G., Smith J.J., et al. Ventricular remodeling in a mouse model of myocardial infarction. Am J Physiol 1998, 274:H1812-H1820.
177. Gao E., Lei Y.H., Shang X., Huang Z.M., Zuo L., Boucher M., et al. A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res 2010, 107:1445-1453.
178. Dhein S. The Langendorff heart. Practical methods in cardiovascular research 2005, 155-172. Springer. S. Dhein, F. Mohr, M. Delmar (Eds.).
179. Zhang G., Zhou B., Zheng Y., Feng K., Rao L., Zhang J., et al. Time course proteomic profile of rat acute myocardial infarction by SELDI-TOF MS analysis. Int J Cardiol 2009, 131:225-233.
180. Jacquet S., Yin X., Sicard P., Clark J., Kanaganayagam G.S., Mayr M., et al. Identification of cardiac myosin-binding protein C as a candidate biomarker of myocardial infarction by proteomics analysis. Mol Cell Proteomics 2009, 8:2687-2699.
181. Cordwell S.J., Edwards A.V., Liddy K.A., Moshkanbaryans L., Solis N., Parker B.L., et al. Release of tissue-specific proteins into coronary perfusate as a model for biomarker discovery in myocardial ischemia/reperfusion injury. J Proteome Res 2012, 11:2114-2126.
182. Addona T.A., Shi X., Keshishian H., Mani D.R., Burgess M., Gillette M.A., et al. A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol 2011, 29:635-643.
183. von Zur Muhlen C., Schiffer E., Zuerbig P., Kellmann M., Brasse M., Meert N., et al. Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J Proteome Res 2009, 8:335-345.
184. Delles C., Schiffer E., von Zur Muhlen C., Peter K., Rossing P., Parving H.H., et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens 2010, 28:2316-2322.
185. von zur Muhlen C., Schiffer E., Sackmann C., Zurbig P., Neudorfer I., Zirlik A., et al. Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Mol Cell Proteomics 2012, 11. [M111 013847].
186. Gomaraschi M., Sinagra G., Serdoz L.V., Pitzorno C., Fonda M., Cattin L., et al. The plasma concentration of Lpa-I:A-II particles as a predictor of the inflammatory response in patients with ST-elevation myocardial infarction. Atherosclerosis 2009, 202:304-311.